Angus Thompson
Abstract
Open-access reader
Like all proton‐pump inhibitors (PPIs), esomeprazole has a generally good safety record. However, there is no true lowpotency formulation of esomeprazole available and therefore the growing use of this drug may increase the risk of dosedependent PPI adverse effects, argues Angus Thompson.
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Like all proton‐pump inhibitors (PPIs), esomeprazole has a generally good safety record. However, there is no true lowpotency formulation of esomeprazole available and therefore the growing use of this drug may increase the risk of dosedependent PPI adverse effects, argues Angus Thompson.
Key concepts: Esomeprazole, Medicine, Proton-pump inhibitor, Adverse effect, Intensive care medicine, Internal medicine, Drug, Pharmacology